Positive final KappaMab Ph2b study results in in kappa-type R/R multiple myeloma patients announced July 12, 2023
Imfinzi + Imjudo demonstrated sustained OS benefit in advanced liver cancer with an unprecedented one in four patients alive at four years in HIMALAYA Ph 3 trial July 5, 2023
Datopotamab deruxtecan met dual primary endpoint of PFS in patients with advanced NSCLC in TROPION-Lung01 Phase III trial July 5, 2023
Positive Second Interim Efficacy Analysis from Mitazalimab OPTIMIZE-1 Ph 2 Study in 1st Line Pancreatic Cancer Announced July 5, 2023
Positive 15-month Survival Data From GLORIA Expansion Arm Evaluating NOX-A12 in Combination With Radiotherapy and Avastin in GBM Announced July 5, 2023
Positive Topline Results from Ph 1/2 EPCORE™ NHL-1 Trial of Epcoritamab in Patients with R/R Follicular Lymphoma announced July 5, 2023
RenovoGem™ Delays Cancer Progression by Eight Months in Locally Advanced Pancreatic Cancer July 5, 2023
Ongoing Double-Digit ORR observed for Single Agent Envafolimab in the ENVASARC Phase 2 Pivotal Trial June 28, 2023
FAILED TRIAL: Ph 3 KEYNOTE-585 Trial in GEJ Adenocarcinoma didn’t meet primary endpoint of EFS June 28, 2023
Ph 3 Trial of ADCETRIS (brentuximab vedotin) with Modified Chemo Regimen Shows Non-Inferiority with 3-Year PFS of 94.9% vs Less Tolerable SoC in cHL June 28, 2023
3-Year Update from Phase I Study in Malignant Melanoma: Results Confirm Strong Overall Survival in Patients Treated with UV1 Cancer Vaccine June 28, 2023
ICML 2023: Breyanzi (lisocabtagene maraleucel) Delivers Deep and Durable Responses in R/R FL and MCL in TRANSCEND Clinical Trials June 28, 2023
Updated clinical data from Ph 1/2 KOMET-001 trial of ziftomenib in patients with heavily pretreated and co-mutated R/R NPM1-mutant AML announced June 21, 2023
KEYTRUDA + Trastuzumab and Chemotherapy Met Primary Endpoint of PFS as 1L Treatment in Patients With HER2-Positive Advanced GEJ Adenocarcinoma June 21, 2023
Updated Results from Waldenstrom Macroglobulinemia Cohort of Ongoing Phase 1/2 Clinical Trial of MB-106, CD20-Targeted Autologous CAR T Therapy June 21, 2023
Efficacy Threshold achieved in Stage 2 of the VERSATILE-002 Trial Evaluating PDS0101 and KEYTRUDA® in Head and Neck Cancer June 21, 2023
FDA Clears Addition of Time-based Final Analysis to Pivotal Phase 3 Study of Uproleselan in R/R AML June 21, 2023
mRNA-4157 (V940) + KEYTRUDA Combination Demonstrated a Statistically Significant DMFS Improvement in Patients with High-Risk Stage III/IV Melanoma Following Complete Resection Versus KEYTRUDA June 14, 2023
Enhertu demonstrated clinically meaningful and durable responses in patients across multiple HER2-expressing advanced solid tumours June 14, 2023
